Microneedle patches for vaccination in developing countries

Journal of Controlled Release

Volumn 240, Issue , 2016, Pages 135-141

  Arya, Jaya ^a   Prausnitz, Mark R ^a  

^a Georgia Institute of Technology   (United States)

Author keywords

Delivery devices; Drug delivery; Microneedle; Skin vaccination; Vaccine delivery

Indexed keywords

CONTROLLED DRUG DELIVERY; DEVELOPING COUNTRIES; DRUG DELIVERY; IMMUNIZATION; NEEDLES; TARGETED DRUG DELIVERY; VACCINES; WASTE DISPOSAL;

DELIVERY DEVICE; IMMUNOGENICITY; INFECTIOUS DISEASE; MICRONEEDLE PATCHES; MICRONEEDLES; NEW TECHNOLOGIES; SKIN VACCINATIONS; VACCINE DELIVERY;

DISEASES;

VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; DEVELOPING COUNTRY; DRUG DELIVERY DEVICE; DRUG MANUFACTURE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE PERSONNEL; HUMAN; IMMUNITY; MEDICAL EDUCATION; MICRONEEDLE; MICRONEEDLE PATCH; NEEDLESTICK INJURY; PRIORITY JOURNAL; VACCINATION; ANIMAL; COMMUNICABLE DISEASE; COMMUNICABLE DISEASE CONTROL; ECONOMICS; INTRADERMAL DRUG ADMINISTRATION; MICROINJECTION; NEEDLE; PROCEDURES; STANDARDS; TRANSDERMAL PATCH;

ANIMALS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; HUMANS; INJECTIONS, INTRADERMAL; MICROINJECTIONS; NEEDLES; TRANSDERMAL PATCH; VACCINATION;

EID: 84949425343     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.11.019     Document Type: Article

References (118)

1. [1] WHO, Global Immunization Data July 2014. (Available from) http://www.who.int/immunization/monitoring_surveillance/global_immunization_data.pdf, July 30 2015.
2. [2] CDC, Measles Vaccination. (Available from) http://www.cdc.gov/measles/vaccination.html, July 30 2015.
3. [3] Institute for Health Metrics and Evaluation (IHME), GBD Database. 2014, IHME, University of Washington, Seattle, WA (Available from). ([http://www.healthdata.org/search-gbd-data?s=measles], Accessed [July 30 2015]).
4. [4] LaMontagne, D.S., et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull. World Health Organ. 89:11 (2011), 821–830.
5. [5] Shen, A.K., Fields, R., McQuestion, M., The future of routine immunization in the developing world: challenges and opportunities. Glo. Health: Sci. Pract. 2:4 (2014), 381–394.
6. [6] Linkins, R.W., et al. Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt. Bull. World Health Organ. 73:5 (1995), 589–595.
7. [7] LaFond, A., et al. Drivers of routine immunization coverage improvement in Africa: findings from district-level case studies. Health Policy Plan. 30:3 (2015), 298–308.
8. [8] Favin, M., et al. Why children are not vaccinated: a review of the grey literature. Int. Heart 4:4 (2012), 229–238.
9. [9] Grassly, N.C., et al. New strategies for the elimination of polio from India. Science 314:5802 (2006), 1150–1153.
10. [10] Sudfeld, C.R., Navar, A.M., Halsey, N.A., Effectiveness of measles vaccination and vitamin A treatment. Int. J. Epidemiol. 39:Suppl. 1 (2010), i48–i55.
11. [11] Madhi, S.A., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N. Engl. J. Med. 362:4 (2010), 289–298.
12. [12] Vesikari, T., et al. Safety and efficacy of a pentavalent human–bovine (WC3) reassortant rotavirus vaccine. N. Engl. J. Med. 354:1 (2006), 23–33.
13. [13] Bhandari, N., et al. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet 383:9935 (2014), 2136–2143.
14. [14] Jafari, H., et al. Polio eradication. Efficacy of inactivated poliovirus vaccine in India. Science (New York, N.Y.) 345:6199 (2014), 922–925.
15. [15] Fenner, F., Smallpox and its eradication. History of International Public Health; No. 6, 1988, World Health Organization, Geneva, c1988.
16. [16] Initiative, W.G.P.E., Polio Eradication & Endgame Strategic Plan 2013–2018. 2013, World Health Organization, Geneva, Switzerland.
17. [17] The Cost of a broken vaccine cold chain part two, financial cost. ([February 25]; Available from) http://www.csafeglobal.com/the-cost-of-a-broken-vaccine-cold-chain-part-two-financial-cost-1, Wednesday, September 17 2014.
18. [18] Das, P., Revolutionary vaccine technology breaks the cold chain. Lancet Infect. Dis., 4(12), 2004, 719.
19. [19] WHO, Guidelines on the International Packaging and Shipping of Vaccines. 2005.
20. [20] VPPAG, Generic Preferred Product Profile for Vaccines. 2015.
21. [21] Alliance, T.W.B.G., Immunization Financing Toolkit: A Resource for Policy-makers and Program Managers. 2010 (August 2 2015).
22. [22] Miller, M.A., Pisani, E., The cost of unsafe injections. Bull. World Health Organ. 77:10 (1999), 808–811.
23. [23] Kermode, M., Unsafe injections in low-income country health settings: need for injection safety promotion to prevent the spread of blood-borne viruses. Health Promot. Int. 19:1 (2004), 95–103.
24. [24] WHO, Injection safety policy and global campaign. (Available from) www.who.int/injection_safety/global-campaign/en/, July 30 2015.
25. [25] Drain, P.K., Nelson, C.M., Lloyd, J.S., Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries. Bull. World Health Organ. 81:10 (2003), 726–731.
26. [26] Haidari, L.A., et al. One size does not fit all: the impact of primary vaccine container size on vaccine distribution and delivery. Vaccine 33:28 (2015), 3242–3247.
27. [27] WHO, WHO policy statement: multi-dose vial policy (MDVP): handling of multi-dose vaccine vials after opening. 2014.
28. [28] Clements, C.J., Larsen, G., Jodar, L., Technologies that make administration of vaccines safer. Vaccine 22:15–16 (2004), 2054–2058.
29. [29] PATH, Some vaccine costs are hidden below the surface. (Available from) http://www.path.org/publications/files/TS_opt_banner_hippo.pdf, March 15 2015.
30. [30] Lydon, P., et al. Health system cost of delivering routine vaccination in low-and lower-middle income countries: what is needed over the next decade?. Bull. World Health Organ. 92:5 (2014), 382–384.
31. [31] UNICEF, MR vaccine supplier prices. (Available from) http://www.unicef.org/supply/files/MR.pdf, 3 August 2015.
32. [32] Measles and Rubella move fast. (Available from) http://www.cdc.gov/globalhealth/measles/pdf/measles-factsheet2015.pdf, 3 August 2015.
33. [33] Kim, Y.C., Park, J.H., Prausnitz, M.R., Microneedles for drug and vaccine delivery. Adv. Drug Deliv. Rev. 64:14 (2012), 1547–1568.
34. [34] Pettis, R.J., Harvey, A.J., Microneedle delivery: clinical studies and emerging medical applications. Ther. Deliv. 3:3 (2012), 357–371.
35. [35] Nestle, F.O., et al. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9:10 (2009), 679–691.
36. [36] Zehrung, D., Jarrahian, C., Wales, A., Intradermal delivery for vaccine dose sparing: overview of current issues. Vaccine 31:34 (2013), 3392–3395.
37. [37] van der Maaden, K., Jiskoot, W., Bouwstra, J., Microneedle technologies for (trans)dermal drug and vaccine delivery. J. Control. Release 161:2 (2012), 645–655.
38. [38] Vrdoljak, A., Review of recent literature on microneedle vaccine delivery technologies. Vaccine: Devel. Ther., 2013.
39. [39] Vrdoljak, A., et al. Coated microneedle arrays for transcutaneous delivery of live virus vaccines. J. Control. Release 159:1 (2012), 34–42.
40. [40] Bachy, V., et al. Langerin negative dendritic cells promote potent CD8(+) T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc. Natl. Acad. Sci. U. S. A. 110:8 (2013), 3041–3046.
41. [41] Carey, J.B., et al. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Sci. Rep., 4, 2014.
42. [42] Erdos, G., et al. Dissolvable microneedle arrays deliver live adenovirus to the skin for genetic immunization. J. Immunol., 188, 2012, 1.
43. [43] Ryan, E., et al. Microneedle-mediated transdermal bacteriophage delivery. Eur. J. Pharm. Sci. 47:2 (2012), 297–304.
44. [44] Mikszta, J.A., et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74:12 (2006), 6806–6810.
45. [45] Morefield, G.L., Tammariello, R.F., Purcell, B.K., Worsham, P.L., Chapman, J., Smith, L.A., Ulrich, R.G., An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. J. Immune Based Ther. Vacc., 2008, 6(5).
46. [46] Mikszta, J.A., et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191:2 (2005), 278–288.
47. [47] Hiraishi, Y., et al. Bacillus Calmette-Guérin vaccination using a microneedle patch. Vaccine 29:14 (2011), 2626–2636.
48. [48] Wong, Y.L., et al. Drying a tuberculosis vaccine without freezing. Proc. Natl. Acad. Sci. U. S. A. 104:8 (2007), 2591–2595.
49. [49] Matsuo, K., et al. Vaccine efficacy of transcutaneous immunization with amyloid β using a dissolving microneedle array in a mouse model of Alzheimer's disease. J. Neuroimmunol. 266:1–2 (2014), 1–11.
50. [50] Torrisi, B.M., et al. Pocketed microneedles for rapid delivery of a liquid-state botulinum toxin A formulation into human skin. J. Control. Release 165:2 (2013), 146–152.
51. [51] Prow, T.W., et al. Nanopatch-targeted skin vaccination against west Nile virus and Chikungunya virus in mice. Small 6:16 (2010), 1776–1784.
52. [52] Matsuo, K., et al. Transcutaneous immunization using a dissolving microneedle array protects against tetanus, diphtheria, malaria, and influenza. J. Control. Release 160:3 (2012), 495–501.
53. [53] Ding, Z., et al. Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array. Pharm. Res. 28:1 (2011), 145–158.
54. [54] Bal, S., et al. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm. Res. 27:9 (2010), 1837–1847.
55. [55] Ding, Z., et al. Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice. J. Control. Release 136:1 (2009), 71–78.
56. [56] Ding, Z., et al. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharm. Res. 26:7 (2009), 1635–1643.
57. [57] Kim, Y.-C., et al. Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity. J. Control. Release 142:2 (2010), 187–195.
58. [58] Alarcon, J.B., et al. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vaccine Immunol. 14:4 (2007), 375–381.
59. [59] Arnou, R., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 27:52 (2009), 7304–7312.
60. [60] Beran, J., et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med., 7, 2009, 15.
61. [61] Choi, H.J., et al. Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles. J. Control. Release 166:2 (2013), 159–171.
62. [62] Choi, H.J., et al. Stability of influenza vaccine coated onto microneedles. Biomaterials 33:14 (2012), 3756–3769.
63. [63] Fernando, G.J.P., et al. Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses. J. Control. Release 159:2 (2012), 215–221.
64. [64] Fernando, G.J.P., et al. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One, 5(4), 2010, 11.
65. [65] Holland, D., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198:5 (2008), 650–658.
66. [66] Kim, Y.C., et al. Stability kinetics of influenza vaccine coated onto microneedles during drying and storage. Pharm. Res. 28:1 (2011), 135–144.
67. [67] Kim, Y.C., et al. Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles. J. Infect. Dis. 201:2 (2010), 190–198.
68. [68] Kim, Y.C., et al. Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles. J. Control. Release 172:2 (2013), 579–588.
69. [69] Kommareddy, S., et al. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs. Vaccine 31:34 (2013), 3435–3441.
70. [70] Kommareddy, S., et al. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens. J. Pharm. Sci. 101:3 (2012), 1021–1027.
71. [71] Koutsonanos, D.G., et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci. Rep., 2, 2012, 10.
72. [72] Levin, Y., Kochba, E., Kenney, R., Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same?. Vaccine 32:34 (2014), 4249–4252.
73. [73] Martin, M.D., et al. Local response to microneedle-based influenza immunization in the skin. Mbio, 3(2), 2012, 8.
74. [74] Nougarede, N., et al. Nine mu g intradermal influenza vaccine and 15 mu g intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults. Hum. Vacc. Immunother. 10:9 (2014), 2713–2720.
75. [75] Pearton, M., et al. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine 28:37 (2010), 6104–6113.
76. [76] Pearton, M., et al. Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine. Adv. Healthcare Mater. 2:10 (2013), 1401–1410.
77. [77] Puig-Barbera, J., et al. Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011–2012 influenza season: a comparative effectiveness study using the Valencia health care information system. Vaccine 32:42 (2014), 5447–5454.
78. [78] Quan, F.S., et al. Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles. J. Control. Release 147:3 (2010), 326–332.
79. [79] Quan, F.S., et al. Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin. PLoS One, 4(9), 2009, 10.
80. [80] Song, J.M., et al. Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles. Antivir. Res. 88:2 (2010), 244–247.
81. [81] Weldon, W.C., et al. Effect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccine. PLoS One, 7(7), 2012, 8.
82. [82] Yan, L., et al. Advanced materials and nanotechnology for drug delivery. Adv. Mater. 26:31 (2014), 5533–5540.
83. [83] Zhu, Q.Y., et al. Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge. Proc. Natl. Acad. Sci. U. S. A. 106:19 (2009), 7968–7973.
84. [84] Andrianov, A.K., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc. Natl. Acad. Sci. U. S. A. 106:45 (2009), 18936–18941.
85. [85] Guo, L., et al. Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays. Biomed. Microdevices 15:6 (2013), 1077–1085.
86. [86] Yin, D., et al. Hepatitis B DNA vaccine-polycation nano-complexes enhancing immune response by percutaneous administration with microneedle. Biol. Pharm. Bull. 36:8 (2013), 1283–1291.
87. [87] Mikszta, J.A., et al. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8:4 (2002), 415–419.
88. [88] Pattani, A., et al. Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J. Control. Release 162:3 (2012), 529–537.
89. [89] Dean, C.H., et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax (TM)-JE) in non-human primates. Hum. Vaccin. 1:3 (2005), 106–111.
90. [90] Gill, H.S., et al. Cutaneous vaccination using microneedles coated with hepatitis C DNA vaccine. Gene Ther. 17:6 (2010), 811–814.
91. [91] van der Maaden, K., et al. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm. Res. 31:7 (2014), 1846–1854.
92. [92] Chen, X., et al. Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays. J. Control. Release 148:3 (2010), 327–333.
93. [93] Kask, A.S., et al. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 28:47 (2010), 7483–7491.
94. [94] Carey, J.B., et al. Microneedle array design determines the induction of protective memory CD8 < +> T cell responses induced by a recombinant live malaria vaccine in mice. PLoS One, 6(7), 2011, e22442.
95. [95] Laurent, P.E., et al. Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults. Vaccine 28:36 (2010), 5850–5856.
96. [96] Corbett, H.J., et al. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One, 5(10), 2010, e13460.
97. [97] Edens, C., et al. A microneedle patch containing measles vaccine is immunogenic in non-human primates. Vaccine 33:37 (2015), 4712–4718.
98. [98] Edens, C., et al. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine 33:37 (2015), 4683–4690.
99. [99] Huang, J., et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin. Vaccine Immunol. 16:5 (2009), 719–725.
100. [100] Edens, C., et al. Measles vaccination using a microneedle patch. Vaccine 31:34 (2013), 3403–3409.
101. [101] Moon, S., et al. Dose sparing and enhanced immunogenicity of inactivated rotavirus vaccine administered by skin vaccination using a microneedle patch. Vaccine 31:34 (2013), 3396–3402.
102. [102] Hooper, J.W., et al. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25:10 (2007), 1814–1823.
103. [103] Icardi, G., et al. Current evidence on intradermal influenza vaccines administered by Soluvia licensed micro injection system. Hum. Vaccin. Immunother. 8:1 (2012), 67–75.
104. [104] Koutsonanos, D.G., et al. Enhanced immune responses by skin vaccination with influenza subunit vaccine in young hosts. Vaccine 33:37 (2015), 4675–4682.
105. [105] Sullivan, S.P., et al. Dissolving polymer microneedle patches for influenza vaccination. Nat. Med. 16:8 (2010), 915–920.
106. [106] Quan, F.S., et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J. Virol. 84:15 (2010), 7760–7769.
107. [107] Koutsonanos, D.G., et al. Delivery of subunit influenza vaccine to skin with microneedles improves immunogenicity and long-lived protection. Sci. Rep., 2, 2012, 357.
108. [108] Pulit-Penaloza, J.A., et al. A protective role of murine langerin(+) cells in immune responses to cutaneous vaccination with microneedle patches. Sci. Rep., 4, 2014, 6094.
109. [109] Ruutu, M.P., et al. Increasing mechanical stimulus induces migration of Langerhans cells and impairs the immune response to intracutaneously delivered antigen. Exp. Dermatol. 20:6 (2011), 534–536.
110. [110] Birchall, J.C., et al. Microneedles in clinical practice—an exploratory study into the opinions of healthcare professionals and the public. Pharm. Res. 28:1 (2011), 95–106.
111. [111] Lee, B.Y., et al. An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine. Vaccine 33:37 (2015), 4727–4736.
112. [112] Donnelly, R.F., et al. Hydrogel-forming microneedle arrays can be effectively inserted in skin by self-application: a pilot study centred on pharmacist intervention and a patient information leaflet. Pharm. Res., 2014.
113. [113] Norman, J.J., et al. Microneedle patches: usability and acceptability for self-vaccination against influenza. Vaccine 32:16 (2014), 1856–1862.
114. [114] Cosman, F., et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 95:1 (2010), 151–158.
115. [115] Toon, J., Self-administration of flu vaccine with a patch may be feasible. (Available from) http://www.news.gatech.edu/2014/02/26/self-administration-flu-vaccine-patch-may-be-feasible-study-suggests, March 2 2015.
116. [116] Mistilis, M.J., Bommarius, A.S., Prausnitz, M.R., Development of a thermostable microneedle patch for influenza vaccination. J. Pharm. Sci. 104:2 (2015), 740–749.
117. [117] Ameri, M., Wang, X., Maa, Y.F., Effect of irradiation on parathyroid hormone PTH(1–34) coated on a novel transdermal microprojection delivery system to produce a sterile product–adhesive compatibility. J. Pharm. Sci. 99:4 (2010), 2123–2134.
118. [118] Zhang, Y., et al. Development of lidocaine-coated microneedle product for rapid, safe, and prolonged local analgesic action. Pharm. Res. 29:1 (2012), 170–177.